Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
Provided By GlobeNewswire
Last update: Oct 17, 2024
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling
Initial Data from Cohort 1 to be Reported in December 2024
Read more at globenewswire.com
